The Pentagon is looking to accelerate development of the ultra-fast weapons in response to recent testing of hypersonics by Russia and China.

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.